Analysts Issue Forecasts for UTHR FY2026 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Investment analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for United Therapeutics in a research note issued on Monday, November 9th. HC Wainwright analyst M. Caufield expects that the biotechnology company will post earnings of $27.46 per share for the year. HC Wainwright has a “Buy” rating and a $660.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.47 per share. HC Wainwright also issued estimates for United Therapeutics’ Q4 2026 earnings at $8.68 EPS, FY2027 earnings at $30.14 EPS, FY2028 earnings at $30.67 EPS, FY2029 earnings at $40.68 EPS and FY2030 earnings at $53.67 EPS.

A number of other research analysts also recently commented on UTHR. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 28th. TD Cowen boosted their price target on shares of United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 price objective on shares of United Therapeutics in a report on Wednesday, October 14th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a research report on Thursday, October 15th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $676.40.

United Therapeutics Trading Up 1.1%

Shares of NASDAQ:UTHR opened at $588.61 on Wednesday. The company has a market capitalization of $25.07 billion, a PE ratio of 22.21, a P/E/G ratio of 3.97 and a beta of 0.49. United Therapeutics has a twelve month low of $449.58 and a twelve month high of $614.23. The firm has a 50 day simple moving average of $536.90 and a 200-day simple moving average of $534.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business had revenue of $832.50 million during the quarter, compared to analyst estimates of $781.14 million. During the same period last year, the company earned $7.16 earnings per share. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year.

United Therapeutics announced that its board has approved a share buyback program on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This buyback authorization permits the biotechnology company to reacquire up to 8.3% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at United Therapeutics

In related news, Director Christopher Patusky sold 1,210 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $580.00, for a total value of $701,800.00. Following the completion of the sale, the director owned 2,140 shares in the company, valued at $1,241,200. This trade represents a 36.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,614 shares of United Therapeutics stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $584.59, for a total value of $943,528.26. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $189,666,133.37. This trade represents a 0.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 412,238 shares of company stock worth $220,071,746 over the last 90 days. 8.60% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. acquired a new position in United Therapeutics during the second quarter worth about $2,868,735,000. Janus Henderson Group PLC increased its stake in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Jupiter Topco LLC purchased a new position in United Therapeutics in the 2nd quarter valued at approximately $450,140,000. Bank of New York Mellon Corp purchased a new position in United Therapeutics in the 2nd quarter valued at approximately $159,522,000. Finally, Caisse de depot et placement du Quebec acquired a new position in United Therapeutics during the second quarter worth $154,304,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, implying roughly 12% upside from the cited share price. HC Wainwright ratings
• Neutral Sentiment: The company announced participation in November investor conferences, giving investors an opportunity to hear updates but not signaling a specific business development. Investor conference announcement
• Neutral Sentiment: A report listed short interest at zero shares. That figure suggests no reported short position, but offers little clear directional signal for the stock.
• Negative Sentiment: CEO Martine Rothblatt sold shares in multiple transactions on November 6 and 9, while director Christopher Patusky also sold shares on November 9. Insider sales can raise concern about sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC filing

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.